Format

Send to

Choose Destination
See comment in PubMed Commons below
Psychooncology. 2013 Sep;22(9):2110-6. doi: 10.1002/pon.3264. Epub 2013 Feb 28.

Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives.

Author information

  • 1Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA.

Abstract

OBJECTIVE:

The development and increased use of genomic profiling has led to refinement of breast cancer treatment. This study sought to examine medical and surgical oncologists' perceptions of factors related to the translation and integration of Oncotype DX® (Genomic Health, Inc., Redwood City, CA, USA) into routine clinical care.

METHODS:

Twenty oncologists (10 medical and 10 surgical oncologists) participated in qualitative interviews. Questions centered on the following themes: oncologists' perceptions about the clinical utility of testing, the impact of patient preferences on the decision to test and use results to inform treatment decisions, methods of communicating risk associated with test results to patients, and benefits of and barriers to incorporating testing into multidisciplinary care settings.

RESULTS:

Oncologists found Oncotype DX test results useful in their practice but had concerns as well. These included that some oncologists either used testing inappropriately or placed undue emphasis on the results at the expense of other clinical information. The use of intermediate test results, which have less clear clinical implications, incorporating results with patient treatment preferences, and the use of testing in multidisciplinary teams were noted as specific challenges.

CONCLUSION:

Oncologists noted several benefits of testing and also many challenges, despite wide dissemination and common use. Education for health providers should include specific training in how to interpret and communicate the uncertainty inherent in genomic tests while integrating patient preferences to inform treatment decision making.

Copyright © 2013 John Wiley & Sons, Ltd.

KEYWORDS:

21-gene; breast cancer; communication; oncology; physician; qualitative

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk